Fig. 2

Time to SARS-CoV-2 negative conversion (local laboratory tests). ^a The median time to negative conversion was estimated using the Kaplan–Meier method, and the confidence intervals were calculated using the Brookmeyer–Crowley method with double log transformation. ^b A Cox proportional hazards model stratified by the randomization factors (age group and underlying diseases) was used to determine the posterior mean hazard ratio with two-sided 95% credible intervals for the camostat mesilate group relative to the placebo group. ^c Stratified log-rank test with randomization factors (age group and underlying diseases) as stratification factors. ^d Cox proportional hazards model with randomization factors (age group and underlying diseases) as stratification factors and treatment group as the covariate. Age groups: ≥ 65 years vs < 65 years. Underlying diseases: chronic respiratory disease, chronic kidney disease, diabetes mellitus, hypertension, cardiovascular disease, and obesity (body mass index ≥ 30 kg/m²). n/c not calculable